Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA.
Columbia University, New York, NY, 10027, USA.
Curr Atheroscler Rep. 2016 Feb;18(2):8. doi: 10.1007/s11883-016-0560-y.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.
心血管疾病（CVD）是全球发病率和死亡率的主要原因。尽管他汀类药物治疗 CVD 取得了成功，但仍有许多患者存在 CVD 高风险。依折麦布是一种抑制肠道胆固醇吸收的非他汀类药物，可降低低密度脂蛋白胆固醇（LDL-C）。多项评估依折麦布治疗作用的临床研究得出了关于其安全性和有效性的数据不一致。在这篇综述中，我们讨论了这些研究的结果，以及依折麦布用于降低 LDL-C 和减少心血管事件的潜在适应证。
